Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.62 0.00 (0.00%)
As of 03:59 PM Eastern
Compare

MDNA vs. IPA, APM, GXE, CGC, and WMD

Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), and WeedMD (WMD). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (CVE:IPA) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

ImmunoPrecise Antibodies has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. ImmunoPrecise Antibodies' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise AntibodiesN/A N/A N/A
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

ImmunoPrecise Antibodies has higher revenue and earnings than Medicenna Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
Medicenna Therapeutics Neutral

Summary

ImmunoPrecise Antibodies and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Andean Precious Metals?

Andean Precious Metals (CVE:APM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Andean Precious Metals has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Andean Precious Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Andean Precious MetalsC$154.78M0.88C$37.41MC$0.512.55
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

Andean Precious Metals has a net margin of 16.17% compared to Medicenna Therapeutics' net margin of -533,640.00%. Andean Precious Metals' return on equity of 20.32% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Andean Precious Metals16.17% 20.32% 4.13%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Andean Precious Metals has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 2.84393, meaning that its share price is 184% more volatile than the S&P 500.

13.2% of Andean Precious Metals shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 69.4% of Andean Precious Metals shares are owned by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Andean Precious Metals. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Andean Precious Metals. Andean Precious Metals' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Andean Precious Metals Neutral
Medicenna Therapeutics Neutral

Summary

Andean Precious Metals beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Gear Energy?

Gear Energy (TSE:GXE) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

2.4% of Gear Energy shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 7.6% of Gear Energy shares are owned by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gear Energy5.77% 3.52% 4.84%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Gear Energy has a beta of 3.52, meaning that its share price is 252% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 2.84393, meaning that its share price is 184% more volatile than the S&P 500.

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Gear Energy. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Gear Energy. Gear Energy's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Gear Energy Neutral
Medicenna Therapeutics Neutral

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Canadian Gold (CVE:CGC) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Canadian GoldN/A -92.98% -48.06%
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

0.3% of Canadian Gold shares are owned by institutional investors. Comparatively, 0.4% of Medicenna Therapeutics shares are owned by institutional investors. 43.3% of Canadian Gold shares are owned by company insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Canadian Gold. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Canadian Gold. Canadian Gold's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
Canadian Gold Neutral
Medicenna Therapeutics Neutral

Canadian Gold has a beta of -1.586234, meaning that its share price is 259% less volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 2.84393, meaning that its share price is 184% more volatile than the S&P 500.

Summary

Canadian Gold and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

WeedMD (CVE:WMD) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
WeedMDN/A N/A N/A
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

Medicenna Therapeutics has lower revenue, but higher earnings than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than WeedMD. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for WeedMD. WeedMD's average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
WeedMD Neutral
Medicenna Therapeutics Neutral

Summary

WeedMD and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$51.72MC$446.03MC$6.24BC$11.72B
Dividend YieldN/A3.86%2.73%6.22%
P/E Ratio-4.134.1929.0423.83
Price / SalesN/A6,879.71477.1013.46
Price / Cash1.1513.1327.6282.69
Price / Book8.3377.749.674.48
Net Income-C$25.98M-C$96.07MC$3.55BC$300.68M
7 Day Performance8.77%0.71%1.70%0.12%
1 Month PerformanceN/A3.87%5.62%2.88%
1 Year Performance-40.38%48.54%34.42%57.78%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.62
flat		N/AN/AC$51.72MN/AN/A20
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/AN/AC$162.08MC$19.47MN/A80
APM
Andean Precious Metals
N/AC$1.29
+7.5%		N/AN/AC$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/AN/AC$126.35MN/AN/A3,150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel